ConSynance Therapeutics
ConSynance Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming scientific discoveries into therapies for rare central nervous system disorders, with a focus on neuropsychiatric conditions such as Prader-Willi Syndrome. They develop innovative treatments targeting neurotransmitter dysregulation, including CSTI-500, a triple monoamine reuptake inhibitor, and CSTI-100/HBS-102, a Melanin-Concentrating-Hormone Receptor 1 antagonist.
Industries
Nr. of Employees
small (1-50)
ConSynance Therapeutics
Health Sciences Campus, 11 University Place, Rensselaer, NY 12144
Patents
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US-9604960-B2
View DetailsAryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US-9034899-B2
View DetailsCrystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US-8815894-B2
View Details7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
US-8802696-B2
View Details
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US-9604960-B2
View DetailsAryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US-9034899-B2
View DetailsCrystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US-8815894-B2
View Details7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
US-8802696-B2
View DetailsProducts
CSTI-500
An oral, once-daily triple monoamine reuptake inhibitor designed to modulate serotonin, dopamine, and norepinephrine; developed for hyperphagia and neurobehavioral symptoms in Prader-Willi Syndrome and hypothalamic obesity. Phase I data report safety, ~50-hour half-life, PET target engagement, and bioequivalence of a capsule formulation; program positioned to enter Phase II.
HBS-102 (formerly CSTI-100)
A melanin-concentrating-hormone receptor 1 (MCHR1) antagonist developed for rare neurological indications (including potential applications in REM-sleep dysregulation and energy regulation). Development and commercialization rights are partnered globally except for Greater China, where original developer retains rights.
CSTI-200
A potent and selective GlyT-1 inhibitor in preclinical development intended to treat L-DOPA-induced dyskinesia in Parkinson's disease; characterized by competitive binding properties and favorable ADME/DMPK.
CSTI-500
An oral, once-daily triple monoamine reuptake inhibitor designed to modulate serotonin, dopamine, and norepinephrine; developed for hyperphagia and neurobehavioral symptoms in Prader-Willi Syndrome and hypothalamic obesity. Phase I data report safety, ~50-hour half-life, PET target engagement, and bioequivalence of a capsule formulation; program positioned to enter Phase II.
HBS-102 (formerly CSTI-100)
A melanin-concentrating-hormone receptor 1 (MCHR1) antagonist developed for rare neurological indications (including potential applications in REM-sleep dysregulation and energy regulation). Development and commercialization rights are partnered globally except for Greater China, where original developer retains rights.
CSTI-200
A potent and selective GlyT-1 inhibitor in preclinical development intended to treat L-DOPA-induced dyskinesia in Parkinson's disease; characterized by competitive binding properties and favorable ADME/DMPK.
Services
Co-development, licensing, and strategic partnership activities with other biopharma organizations and patient advocacy groups to advance rare-disease programs.
Co-development, licensing, and strategic partnership activities with other biopharma organizations and patient advocacy groups to advance rare-disease programs.
Expertise Areas
- Clinical trial management for rare CNS disorders
- Small-molecule CNS drug discovery and lead optimization
- Translational neuroscience and biomarker qualification
- Pharmacokinetics and DMPK
Key Technologies
- Positron emission tomography (PET) for CNS target engagement
- Triple monoamine reuptake inhibition (small molecule)
- Melanin-concentrating hormone receptor 1 (MCHR1) antagonism
- GlyT-1 inhibition
News & Updates
ConSynance will sponsor and present a poster at the 2025 “United in Hope” International Prader-Willi Syndrome Conference, sharing findings from a Phase 1 trial of CSTI-500.
CEO Shuang Liu will attend the BIO International Convention in Boston, MA, to discuss collaborations, investment opportunities, and updates on CSTI-500.
ConSynance joined policymakers, researchers, and families at the House of Lords for the “Taking PWS to Parliament” event, highlighting the needs of those with PWS.
Research Director Sarah Sheldrick presented updates on CSTI-500 and ongoing clinical trials for PWS during the webinar organized by FPWR UK and PWSA UK.
ConSynance reaffirmed its dedication to developing therapeutics for PWS on Rare Disease Day, emphasizing the need for effective treatments.
The FDA approved VYKAT™ XR (DCCR) for hyperphagia in PWS, marking a significant advancement in treatment options.
ConSynance will sponsor and present a poster at the 2025 “United in Hope” International Prader-Willi Syndrome Conference, sharing findings from a Phase 1 trial of CSTI-500.
CEO Shuang Liu will attend the BIO International Convention in Boston, MA, to discuss collaborations, investment opportunities, and updates on CSTI-500.
ConSynance joined policymakers, researchers, and families at the House of Lords for the “Taking PWS to Parliament” event, highlighting the needs of those with PWS.
Research Director Sarah Sheldrick presented updates on CSTI-500 and ongoing clinical trials for PWS during the webinar organized by FPWR UK and PWSA UK.
ConSynance reaffirmed its dedication to developing therapeutics for PWS on Rare Disease Day, emphasizing the need for effective treatments.
The FDA approved VYKAT™ XR (DCCR) for hyperphagia in PWS, marking a significant advancement in treatment options.